Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical AdvisorExpanding the Phase ...
Ventyx Biosciences Inc (NASDAQ:VTYX) stock is trading lower on Monday. The company released results from the Phase 2 trial of allosteric TYK2 inhibitor VTX958 in participants with moderately to ...
InvestorsHub on MSN
Ventyx shares drop after pushing back Phase 2 interim results to early 2026
Ventyx Biosciences (NASDAQ:VTYX) slid 10% on Tuesday after the biotech firm said it will postpone the interim analysis from ...
Ventyx Biosciences is terminating most work on its lead drug candidate for inflammatory diseases despite achieving the main goal of a mid-stage study in plaque psoriasis. The results fall short of ...
19don MSN
Ventyx Biosciences (VTYX) Outlook Strengthened by Cost Optimization and Positive Clinical Data
Ventyx Biosciences Inc. (NASDAQ:VTYX) is among the hottest SMID-cap stocks so far in 2025. On November 7, TheFly reported that Canaccord Genuity modestly increased its price target on the company’s ...
Piper Sandler 37 th Annual Healthcare Conference details : Fireside Chat Date: Wednesday, December 3, 2025 Time: 4:00 – 4:25 PM ET ...
ENCINITAS, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that ...
ENCINITAS, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that ...
Ventyx Biosciences Inc (NASDAQ:VTYX) shares are surging Thursday after the company announced positive Phase 2 study results for VTX3232 in patients with obesity and cardiovascular risk factors. What ...
The company is developing a drug that utilizes the same mechanism as a recently approved one. Analysts believe this gives Ventyx very high potential for success. The treatment in question is Bristol ...
Investing.com -- Ventyx Biosciences (NASDAQ:VTYX) stock fell 10% after the clinical-stage biopharmaceutical company announced it would delay the release of interim analysis data from its Phase 2 ...
Ventyx, an ABB company that provides enterprise software solutions for energy and industrial infrastructure clients, has recruited one of the brightest bulbs on the smart grid chandelier to spearhead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results